Cristian Sandoval-Acuña

Cristian Sandoval-Acuña

Auto-generated profile, based on publicly available information

Cristian Sandoval-Acuña

Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
NTNatalia Torrealba
Natalia Torrealba
VTVeronika Tomkova
Veronika Tomkova
SJSukanya B. Jadhav
Sukanya B. Jadhav
KBKristyna Blazkova
Kristyna Blazkova
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed marked cytostatic, cytotoxic, and migrastatic properties in vitro, and it significantly suppressed tumor growth and metastasis in vivo. The underlying molecular mechanisms included (i) impairment of iron-sulfur [Fe-S] cluster/heme biogenesis, leading to destabilization and loss of activity of [Fe-S] cluster/heme containing enzymes, (ii) inhibition of mitochondrial respiration leading to mitochondrial reactive oxygen species production, resulting in dysfunctional mitochondria with markedly reduced supercomplexes, and (iii) fragmentation of the mitochondrial network and induction of mitophagy. Mitochondrial targeting of deferoxamine represents a way to deprive cancer cells of biologically active iron, which is incompatible with their proliferation and invasion, without disrupting systemic iron metabolism. Our findings highlight the importance of mitochondrial iron metabolism for cancer cells and demonstrate repurposing deferoxamine into an effective anticancer drug via mitochondrial targeting. Significance: These findings show that targeting the iron chelator deferoxamine to mitochondria impairs mitochondrial respiration and biogenesis of [Fe-S] clusters/heme in cancer cells, which suppresses proliferation and migration and induces cell death.

11 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
SFSebastián Fuentes-Retamal
Sebastián Fuentes-Retamal
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
LPLiliana Peredo-Silva
Liliana Peredo-Silva
DGDaniela Guzmán-Rivera
Daniela Guzmán-Rivera
MPMario Pavani
Mario Pavani
JFJorge Ferreira
Jorge Ferreira
The mitochondrion has emerged as a promising therapeutic target for novel cancer treatments because of its essential role in tumorigenesis and resistance to chemotherapy. Previously, we described a natural compound, 10-((2,5-dihydroxybenzoyl)oxy)decyl) triphenylphosphonium bromide (GA-TPP+C10), with a hydroquinone scaffold that selectively targets the mitochondria of breast cancer (BC) cells by binding to the triphenylphosphonium group as a chemical chaperone; however, the mechanism of action remains unclear. In this work, we showed that GA-TPP+C10 causes time-dependent complex inhibition of the mitochondrial bioenergetics of BC cells, characterized by (1) an initial phase of mitochondrial uptake with an uncoupling effect of oxidative phosphorylation, as previously reported, (2) inhibition of Complex I-dependent respiration, and (3) a late phase of mitochondrial accumulation with inhibition of α-ketoglutarate dehydrogenase complex (αKGDHC) activity. These events led to cell cycle arrest in the G1 phase and cell death at 24 and 48 h of exposure, and the cells were rescued by the addition of the cell-penetrating metabolic intermediates l-aspartic acid β-methyl ester (mAsp) and dimethyl α-ketoglutarate (dm-KG). In addition, this unexpected blocking of mitochondrial function triggered metabolic remodeling toward glycolysis, AMPK activation, increased expression of proliferator-activated receptor gamma coactivator 1-alpha (pgc1α) and electron transport chain (ETC) component-related genes encoded by mitochondrial DNA and downregulation of the uncoupling proteins ucp3 and ucp4, suggesting an AMPK-dependent prosurvival adaptive response in cancer cells. Consistent with this finding, we showed that inhibition of mitochondrial translation with doxycycline, a broad-spectrum antibiotic that inhibits the 28 S subunit of the mitochondrial ribosome, in the presence of GA-TPP+C10 significantly reduces the mt-CO1 and VDAC protein levels and the FCCP-stimulated maximal electron flux and promotes selective and synergistic cytotoxic effects on BC cells at 24 h of treatment. Based on our results, we propose that this combined strategy based on blockage of the adaptive response induced by mitochondrial bioenergetic inhibition may have therapeutic relevance in BC.

20 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SJSukanya B Jadhav
Sukanya B Jadhav
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
YPYaiza Pacior
Yaiza Pacior
PPPetra Potomova
Petra Potomova
KKKristyna Klanicova
Kristyna Klanicova
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
Iron chelation has been proposed as an anti-cancer approach; however, iron chelators are generally non-specific for cancer cells and rely on the higher sensitivity of malignant cells to iron deprivation and accumulation of the drug in tumor tissue via the enhanced permeability and retention effect. Here, we present mitochondrially targeted deferasirox (mitoDFX), a redox-active iron chelator that deprives cells of biologically active iron, as evidenced by a decrease in [Fe-S] cluster and heme-containing proteins. Notably, mitoDFX also depletes the major cellular antioxidant glutathione and induces lipid peroxidation, both of which are hallmarks of ferroptosis, resulting in selective induction of cell death in cancer cells. In summary, targeting deferasirox into the mitochondria results in an agent that has a unique ability to elicit iron deprivation and produce toxic lipid peroxides via its redox activity, thus harnessing the dual nature of iron in a single molecule to combat cancer.

31 March 2023
Verified
Other
Open access
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
NTNatalia Torrealba
Natalia Torrealba
VTVeronika Tomkova
Veronika Tomkova
SJSukanya B. Jadhav
Sukanya B. Jadhav
KBKristyna Blazkova
Kristyna Blazkova
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
Supplementary Methods, Tables and Figures

31 March 2023
Verified
Other
Open access
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
NTNatalia Torrealba
Natalia Torrealba
VTVeronika Tomkova
Veronika Tomkova
SJSukanya B. Jadhav
Sukanya B. Jadhav
KBKristyna Blazkova
Kristyna Blazkova
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
High Resolution Supplementary Figure S4

31 March 2023
Verified
Other
Open access
CSCristian Sandoval-Acuña
Cristian Sandoval-Acuña
NTNatalia Torrealba
Natalia Torrealba
VTVeronika Tomkova
Veronika Tomkova
SJSukanya B. Jadhav
Sukanya B. Jadhav
KBKristyna Blazkova
Kristyna Blazkova
Jaroslav TruksaJaroslav Truksa
Jaroslav Truksa
High Resolution Supplementary Figure 2